Antithrombotic and fibrinolytic factors

Veterinary Clinics of North America - Small Animal Practice

Volumn 26, Issue 5, 1996, Pages 1111-1127

  Welles, Elizabeth G ^a  

^a AUBURN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; PLASMINOGEN;

ANIMAL; ANIMAL DISEASE; BLOOD; BLOOD CLOTTING; CAT; CAT DISEASE; DOG; DOG DISEASE; FIBRINOLYSIS; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; THROMBOSIS;

ANIMALS; ANTITHROMBIN III; BLOOD COAGULATION; CAT DISEASES; CATS; DOG DISEASES; DOGS; FIBRINOLYSIS; PLASMINOGEN; THROMBOSIS;

EID: 0030238963     PISSN: 01955616     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0195-5616(96)50058-6     Document Type: Article

References (136)

1. Allaart CF, Poort SR, Rosendaal FR, et al Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet 341134-138, 1993
2. Bartoloni C, Guidi L, Tricerri A, et al Latent coagulation disorders evaluated by the assay of plasma thrombin-antithrombin III complexes in a large series of 'solid tumours'. Oncology 49426-430, 1992
3. Bauer KA, Rosenberg RD The pathophysiology of the prethrombotic state in humans Insights gained from studies using markers of hemostatic system activation. Blood 70343-350, 1987
4. Bertina RM, van Wijngaarden A, Reinalda-Poot J, et al Determination of plasma protein S-The protein cofactor of activated protein C. Thromb Haemost 53268-272, 1985
5. Bevers EM, Galli M, Barbui T, et al Lupus anticoagulants IgGs (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 66629-632, 1991
6. Blasi F Molecular mechanisms of protease-mediated tumor invasiveness. J Sure Oncol 3(suppl)21-23, 1993
7. Blasi F Urokinase and urokinase receptor A paracrine/autocrine system regulating cell migration and invasiveness. Bioessays 15105-111, 1993
8. Boisclair MD, Lane DA, Wilde JT, et al A comparative evaluation of assays for markers of activated coagulation and/or fibrinolysis Thrombin-antithrombin complex, D-dimer and fibrinogen/fibrin fragment E antigen. Br J Haematol 74471-479, 1990
9. Bolton GR Feline cardiology. Feline Pract 542-44, 1975
10. Bond BR, Fox PR Advances in feline cardiomyopathy. Vet Clin North Am Small Arum Pract 141021-1038, 1984
11. Boudreaux MK, Weiss RC, Cox N, et al Evaluation of antithrombin-III activity as a coindicator of disseminated intravascular coagulation in cats with induced feline infectious peritonitis virus infection. Am J Vet Res 501910-1913, 1989
12. Bovill EG, Bauer KA, Dickermann JD, et al The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. Blood 73712-717, 1989
13. Broekmans AW, Conard J Hereditary protein C deficiency. In RM Bertina (ed) Protein C and Related Proteins. London, Churchill-Livingstone Longman Group, 1988, pp 160-181
14. Busch C, Cancilla P, Debault LE, et al Use of endothelium cultured on microcarriers as a model for the microcirculation. Lab Invest 47498-504, 1992
15. Chapman HA Jr, Vavrin Z, Hibbs JB Jr, et al Macrophage fibrinolytic activity Identification of two pathways of plasmin formation by intact cells and of a plasminogen activator inhibitor. Cell 28653-662, 1982
16. Clouse LH, Comp PC The regulation of hemostasis The protein C system. N Engl J Med 3141298-1304, 1986
17. Cohen RL, Shuman MA Tumor cells utilize cell-bound plasmin to degrade basement membranes. Clin Res 38466A, 1990
18. Comp PC, Esmon CT Recurrent thromboembolism in patients with a partial deficiency of protein S. N Engl J Med 3111525-1528, 1984
19. Comp PC, Thurnau GR, Welsh J, et al Functional and immunological protein S levels are decreased during pregnancy. Blood 68881-885, 1985
20. D'Angelo A, Vigano-D'Angelo S, Esmon CT, et al Acquired deficiency of protein S Protein S activity during oral anticoagulation, in liver disease, and in disseminated intravascular coagulation. J Clin Invest 811445-1454, 1988
21. Dahlback B The protein C anticoagulant system Inherited defects as basis for venous thrombosis. Thromb Res 771-43, 1995
22. Dahlback B, Carlsson M, Svensson PJ Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulation response to activated protein C Prédiction of a cofactor to activated protein C. Proc Natl Acad Sei U S A 901004-1008, 1993
23. Dahlback B, Hildebrand B Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sei USA 811396-1400, 1994
24. Dahlback B, Stenflo J High molecular weight complex in human plasma between vitamin K-dependent protein S and complement component C4b-binding protein. Proc Natl Acad Sei U S A 782512-2516, 198i
25. Dahlback B, Stenflo J The protein C anticoagulant system. In Stamatoyannopoulos G, Nienhuis AW, Majerus PW, et al (eds) The Molecular Basis of Blood Diseases. Philadelphia, WB Saunders, 1994, pp 599-628
26. Dahlback B Inhibition of protein Ca cofactor function of human and bovine protein S by C4b-binding protein. J Biol Chem 26112,022-12,027, 1986
27. Dahlback B Protein S and C4b-binding protein Components involved in the regulation of protein C anticoagulant system. Thromb Haemost 6649-61, 1991
28. Dale S, Gogstad GO, Brosstad F, et al Comparison of three D-dimer assays for the diagnosis of DVT ELISA, latex and an immunofiltration assay (Nycocard D-Dimer). Thromb Haemost 71270-274, 1994
29. Davis RD, Picoff RC Low plasminogen levels and liver disease. Am J Clin Pathol 59661-665, 1987
30. de Groot PG, Derksen RHWM Protein C pathway, antiphospholipid antibodies and thrombosis. Lupus 3229-233, 1994
31. de Groot PC, Costing JD, Derksen RHWM Antiphospholipid antibodies Specificity and pathophysiology. Ballieres Clin Haematol 6691-709, 1993
32. Debault LE, Esmon NL, Oison JR, et al Distribution of the thrombomodulin antigen in the rabbit vasculature. Lab Invest 54172-178, 1986
33. Deitcher SR, Eisenberg MD Elevated concentrations of cross-linked fibrin degradation products in plasma An early marker of gram-negative bacteremia. Chest 10311071112, 1993
34. Demers C, Henderson P, Blajchman MA, et al Antithrombin III assay based on Factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition. Thromb Haemost 69231235, 1993
35. Dieval J, Nguyen G, Gross S, et al A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1. Blood 3528-532, 1991
36. Dittman WA, Majerus PW Structure and function of thrombomodulin A natural anticoagulant. Blood 75329-336, 1990
37. Edens LM, Morris DD, Prasse KW, et al Hypercoagulable state associated with a deficiency of protein C in a Thoroughbred colt. ] Vet Intern Med 7190-193, 1993
38. Ellis DR, Eaton AS, Plantk MC, et al A comparative evaluation of ELISAs for D-dimer and related fibrin(ogen) degradation products. Blood Coagul Fibrinolysis 4537-549, 1993
39. Esmon CT, Esmon NL, Harris KW Complex formation between thrombin and thrombomodulin inhibits both thrombin catalyzed fibrin formation and factor V activation. J Biol Chem 2577944-7947, 1982
40. Esmon CT Cell mediated events that control blood coagulation and vascular injury. Annu Rev Cell Biol 91-26, 1993
41. Esmon CT Molecular events that control the protein C anticoagulant pathway. Thromb Haemost 7029-35, 1993
42. Esmon CT The protein C anticoagulant pathway. Arterioscler Thromb 12135-145, 1992
43. Esmon NL, Carroll RC, Esmon CT Thrombomodulin blocks the ability of thrombin to activate platelets. J Biol Chem 25812,238-12,242, 1983
44. Faioni EM, Franchi F, Asti D, et al Resistance to activated protein C in nine thrombophilic families Interference in a protein S functional assay. Thromb Haemost 701067-1071, 1993
45. Fair DS, Marlar RA, Levin EG Human endothelial cells synthesize protein S. Blood 671168-1171, 1986
46. Fair DS, Marlar RA Biosynthesis and secretion of factor VII, protein C, protein S, and protein C inhibitor from a human hepatoma cell line. Blood 6764-70, 1986
47. Fay WP, Shapiro AD, Shih JL, et al Brief Report Complete deficiency of plasminogenactivator inhibitor type 1 due to a frameshift mutation. N Engl J Med 32717291733, 1992
48. Fazioli F, Blasi F Urokinase-type plasminogen activator and its receptor New targets for anti-metastatic therapy? Trends Pharmacol Sei 1525-29, 1994
49. Fox PR Feline myocardial disease. In Kirk RW (ed) Current Veterinary Therapy VIII. Philadelphia, WB Saunders Co, 1983, pp 337-348
50. Friberger P Method for the assay of plasminogen in plasma. Scand J Clin Lab Invest 42(suppl. 162)49-57, 1982
51. Fujita T, Gigli I, Nussenzweig V Human C4b-binding protein, II Role of proteolysis of C4b by C3b-inactivator. J Exp Med 1481044-1051, 1978
52. Fujita T, Nussenzweig V The role of C4b-binding protein and blH in proteolysis of C4b and C3b. J Exp Med 150267-276, 1979
53. Gaffney PJ, Cooke DA, Burnand KG Urokinase and its receptor Marker of malignancy? Adv Exp Med Biol 360187-191, 1994
54. Galli M, Comfurius P, Maassen D, et al Anticardiolipin antibodies (ACA) directed not to cardiopin but to a plasma protein cofactor. Lancet 3351544-1547, 1990
55. Gigli I, Fujita T, Nussenzweig V Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator. Proc Natl Acad Sei U S A 766596-6600, 1979
56. Gogstad GO, Dale S, Brosstad F, et al A new assay for measurement of D-dimer based on immunofiltration and staining with gold colloids. Clin Chem 392070-2076, 1993
57. Goldfarb RH, Liotta L Proteolytic enzymes in cancer invasion and metastasis. Semin Thromb Hemost 12294-307, 1986
58. Greene RA Pathophysiology of antithrombin III deficiency. Vet Clin North Am Small Anim Pract 1895-104, 1988
59. Greene RA, Thomas JS Hemostatic disorders Coagulopathies and thrombosis. In Ettinger SJ, Feldman EC (eds) Textbook of Veterinary Internal Medicine Diseases of the Dog and Cat, ed 4, vol 2. Philadelphia, WB Saunders Co, 1995, pp 1946-1963
60. Griffin JH, Evatt B, Beideman C, et al Anticoagulant protein C pathway defective in a majority of thrombophilic patients. Blood 821989-1993, 1993
61. Halbmayer WM, Haushofer A, Schon R, et al The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coagul Fibrinolysis 551-57, 1994
62. Halfman M, Berg DE Venous thrombosis, antithrombin III deficiency. Crit Care Nurs Clin North Am 5499-509, 1993
63. Hamsten A, De Faire U, Walldius G, et al Plasminogen activator inhibitor in plasma Risk factor for recurrent myocardial infarction. Lancet 23-9, 1987
64. Harris EN, Asherson RA, Hughes GR Antiphospholipid antibodies-autoantibodies with a difference. Annu Rev Med 39261-271, 1988
65. Hashimoto K, Prystowsky JH, Baird J, et al Keratinocyte urokinase-type plasminogen activator is secreted as a single chain precursor. J Invest Dermatol 90823-828, 1988
66. Heeb MJ, Mesters RM, Tans G, et al Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C. J Biol Chem 2682872-2877, 1993
67. Heijboer H, Brandjes D, Buller HR, et al Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 3231512-1516, 1990
68. Heiple JM, Ossowski L Human neutrophil plasminogen activator is localized in specific granules and is translocated to the cell surface by exocytosis. J Exp Med 164826-840, 1986
69. Herren T, Bartsch P, Haeberli A, et al Increased thrombin-antithrombin III complexes after l h of physical exercise. J Appl Physiol 732499-2504, 1992
70. High KA Antithrombin III, protein C, and protein S Naturally occurring anticoagulant proteins. Arch Pathol Lab Med 11228-36, 1988
71. Hoek JA, Sturk A, ten Gate JW, et al Laboratory and clinical evaluation of an assay of thrombin-antithrombin III complexes in plasma. Clin Chem 342058-2062, 1988
72. Holland M, Kelley AB, Snyder JR, et al Antithrombin III activity in horses with large colon torsion. Am J Vet Res 47897-900, 1986
73. John MA, Elms MJ, O'Reilly EJ, et al The SimpliRED D Dimer test A novel assay for the detection of cross-linked fibrin degradation products in whole blood. Thromb Res 58273-281, 1990
74. Johnstone IB, Crane S Haemostatic abnormalities in horses with colic-their prognostic value. Equine Vet J 14271-274, 1986
75. Juhan-Vague I, Vague P Interrelations between carbohydrates, lipids, and the hemostatic system in relation to the risk of thrombotic and cardiovascular disease. Am J Obstet Gynecol 163313-315, 1990
76. Kay LA The fibrinolytic system. In Essentials of Haemostasis and Thrombosis. New York, Churchill Livingstone, 1988, pp 96-107
77. Koster T, Rosendaal FR, deRonde F, et al Venous thrombosis due to poor response to activated protein C Leiden thrombophilia study. Lancet 3421503-1506, 1993
78. Kruithof EKO, Tran-Thang C, Gudinchet A, et al Fibrinolysis in pregnancy A study of plasminogen activator inhibitors. Blood 69460-466, 1987
79. Law SKA, Reid KBM Activation and control of the complement. In Male D (ed) Complement. Oxford, UK, IRL Press, 1988, pp 9-27
80. Li A, Taylor FB, Chang AK, et al Functional assay of plasma antithrombin using polyethylene glycol (PEG) defribrinated plasma. Thromb Res 79395-403, 1995
81. Liu S-K Acquired cardiac lesions leading to congestive heart failure in the cat. Am J Vet Res 312071-2088, 1970
82. Lord PF, Wood A, Tilly LP, et al Radiographie and hemodynamic evaluation of cardiomyopathy and thromboembolism in the cat. J Am Vet Med Assoc 164154165, 1974
83. Lorente JA, Garcia-Fgrade LJ, Landin L, et al Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest 1031536-1542, 1993
84. Loskutoff DJ, Sawdey M, Mimuro J Type 1 plasminogen activator inhibitor. In Coller B (ed) Progress in Hemostasis and Thrombosis, vol 9. Philadelphia, WB Saunders, 1989, pp 87-115
85. Love PE, Snatoro SA Antiphospholipid antibodies Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Ann Intern Med 112682-698, 1990
86. Malm J, Laurell M, Dahlback B Changes in the plasma levels of vitamin K-dependent proteins C and S and C4b-binding protein during pregnancy and oral contraception. Br J Haematol 68437-443, 1988
87. Malm J, Laurell M, Nilsson IM, et al Thromboembolic disease-Critical evaluation of laboratory investigation. Thromb Haemost 687-13, 1992
88. Mannucci PM, Giangrande PLF Detection of the prethrombotic state due to procoagulant imbalance. Eur J Haematol 4865-69, 1992
89. Maruyama I, Bell CE, Majerus PW Thrombomodulin is found on endothelium of arteries, veins, capillaries, and lymphatics, and on syncytiotrophoblast of human placenta. J Cell Biol 101363-371, 1985
90. McNeil HP, Simpson RJ, Chesterman CN, et al Antiphospholipid antibodies are directed against a complex antigen that includes a lipid binding inhibitor of coagulation 3-Glycoprotein I (apolipoprotein H). Proc Natl Acad Sei U S A 874120-4124,1990
91. Morris DD Recognition and management of disseminated intravascular coagulation in horses. Vet Clin North Am Equine Pract 4115-143, 1988
92. Murray M, Rushton A Bovine renal amyloidosis A clinicopathologic study. Vet Rec 90210-216, 1972
93. Nagasawa S, Ichihara C, Stroud R Cleavage of C4b by C3b inactivator Production of a nicked form of C4b, C4b', as an intermediate cleavage product of C4b and C3b inactivator. J Immunol 125578-582, 1980
94. Nelsestuen GL, Kisiel W, Discipio RG Interaction of vitamin K-dependent proteins with membranes. Biochemistry 172134-2138, 1978
95. Ogura M, Tanabe N, Nishioka J, et al Biosynthesis and secretion of functional protein S by a human megakaryoblastic cell line (MEG-01). Blood 70301-306, 1987
96. Costing JD, Derksen RHWM, Bobbink WG, et al Antiphospholipid antibodies against a combination of phospholipids with prothrombin, protein C or protein S An explanation for their pathogenic mechanism? Blood 812618-2625, 1983
97. Oosting JD, Derksen RHWM, Entjes HTI, et al Lupus anticoagulant activity is frequently dependent on the presence of β2-glycoprotein L Thromb Haemost 67499502, 1992
98. Pelzer H, Schwarz A, Heimburger N Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 59101-106, 1988
99. Plow EF, Fêlez J, Miles LA Cellular regulation of fibrinolysis. Thromb Haemost 6632-36, 1991
100. Plow EF, Herren T, Redlitz A, et al The cell biology of the plasminogen system. FASEB J 9939-945, 1995
101. Pralong G, Calandra T, Glauser MP, et al Plasminogen activator inhibitor 1 A new prognostic marker in septic shock. Thromb Haemost 61459-462, 1989
102. Prasse KW, Allen D, Moore JN, et al Evaluation of coagulation and fibrinolysis during the prodomal stages of carbohydrate-induced acute laminitis in horses. Am J Vet Res 511950-1955, 1990
103. Prasse KW, Topper MJ, Moore JN, et al Analysis of hemostasis in horses with colic. J Am Vet Med Assoc 5685-693, 1993
104. Ranby M, Norman B, Wallen P A sensitive assay for tissue plasminogen activator. Thromb Res 27743-749, 1982
105. Regan LM, Lamphear BJ, Walker FJ, et al Factor IXa protects factor Villa from activated protein C Factor IXa inhibits activated protein C-catalyzed cleavage of factor Villa at Arg562. J Biol Chem 2699445-9452, 1994
106. Reitsma PH, Poort SR, Allaart CF, et al The spectrum of genetic defects in a panel of 40 Dutch families with symptomatic protein C deficiency type I Heterogeneity and founder effects. Blood 78890-894, 1991
107. Sakata Y, Loskutoff DJ, Gladson CL, et al Mechanism of protein C-dependent clot lysis Role of plasminogen activator inhibitor. Blood 681218-1223, 1986
108. Sawdey MS, Loskutoff DJ Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest 881346-1353, 1988
109. Scharstein J, Ferreira A, Gigli 1, et al Human C4b-binding protein, I Isolation and characterization. J Exp Med 148207-222, 1978
110. Schlechte W, Murano G, Boyd D Examination of the role of the urokinase receptor in human colon cancer-mediated laminin degradation. Cancer Res 496064-6069,1989
111. Schleef RR, Higgins DL, Pillemer E, et al Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. J Clin Invest 8317471752, 1989
112. Schneiderman J, Sawdey MS, Keeton MR, et al Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sei U S A 896998-7002, 1992
113. Schwartz BS, Bradshaw JD Regulation of plasminogen activator inhibitor mRNA levels in lipopolysaccharide-stimulated human monocytes Correlation with production of the protein. J Biol Chem 2677089-7094, 1992
114. Schwarz HP, Heeb MJ, Wencel-Drake JD, et al Identification and quantitation of protein S in human platelets. Blood 661452-1455, 1985
115. Shen L, Dahlback B Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor Villa. J Biol Chem 26918735-18738, 1994
116. Slappendel RJ Disseminated intravascular coagulation. Vet Clin North Am Small Anim Pract 18169-184, 1988
117. Sprengers ED, Kluft C Plasminogen activator inhibitor. Blood 69381-387, 1987
118. Stern DM, Brett J, Harris KW, et al Participation of endothelial cells in the protein C-protein S anticoagulant pathway The synthesis and release of protein S. J Cell Biol 1021971-1978, 1986
119. Suter PF, Fox PR Peripheral vascular disease. In Ettinger SJ, Feldman EC (eds) Textbook of Veterinary Internal Medicine Diseases of the Dog and Cat, ed 4, vol 1. Philadelphia, WB Saunders, 1995, pp 1068-1081
120. Svensson PJ, Dahlback B Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 330517-521, 1994
121. Tabernero MD, Tomas JF, Alberca I, et al Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. Am J Hematol 36249-254, 1991
122. Takahashi H, Tatewaki W, Wada K, et al Thrombin vs plasmin generation in disseminated intravascular coagulation associated with various underlying disorders. Am J Hematol 390-95, 1990
123. Takahashi H, Wada K, Niwano H, et al Comparison of prothrombin fragment 1 + 2 with thrombin-antithrombin III complex in plasma of patients with disseminated intravascular coagulation. Blood Coagul Fibrinolysis 3813-818, 1992
124. Tengborn L, Palmblad S, Wojciechowski}, et al D-dimer and thrombin/ antithrombin 111 complex-Diagnostic tools in deep venous thrombosis? Haemostasis 24344-350, 1994
125. Tran TH, Ducket F Heparin cofactor II determination Levels in normals and patients with hereditary antithrombin III deficiency and disseminated intravascular coagulation. Thromb Haemost 52112-116, 1984
126. van Deventer SJH, Bueller HR, ten Gate JW, et al Experimental endotoxemia in humans Analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 762520-2526, 1990
127. van Wersch JWJ, Houben P, Rijken ] Platelet count, platelet function, coagulation activity and fibrinolysis in the acute phase of inflammatory bowel disease. Eur J Clin Chem Clin Biochem 28513-517, 1990
128. van Wersch JW], Ubachs JMH Blood coagulation and fibrinolysis during normal pregnancy. Eur J Clin Chem Clin Biochem 2945-50, 1991
129. Vigano-D'Angelo S, D'Angelo A, Kaufman MJ, et al Protein S deficiency occurs in the nephrotic syndrome. Ann Intern Med 10742-47, 1987
130. Welles EG, Boudreaux MK, Crager CS, et al Platelet function and antithrombin, plasminogen, and fibrinolytic activities in cats with heart disease. Am J Vet Res 55619-627, 1994
131. Welles EG, Boudreaux MK, Tyler JW Platelet, antithrombin, and fibrinolytic activities in taurine-déficient and taurine-replète cats. Am J Vet Res 541235-1243, 1993
132. Welles EG, Prasse KW, Duncan A, et al Antigenic assay for protein C determination in horses. Am J Vet Res 511075-1079, 1990
133. Welles EG, Prasse KW, Duncan A Chromogenic assay for equine plasminogen. Am J Vet Res 511080-1085, 1990
134. Welles EG, Williams MA, Tyler JW, et al Hemostasis in cows with endotoxin-induced mastitis. Am J Vet Res 541230-1234, 1993
135. Welles EW, Prasse KW, Moore JN Use of newly developed assays for protein C and plasminogen in horses with signs of colic. Am J Vet Res 52345-351, 1991
136. Wiman B, Melbring G, Ramby M Plasminogen activator release during venous stasis and exercise as determined by a new specific assay. Clin Chim Acta 127279-288,1983